Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Conditions
Hepatitis C
Interventions
Telaprevir, Peginterferon alfa-2b, Ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
3 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 10 more
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
25
States / cities
Bakersfield, California • Pasadena, California • San Diego, California + 22 more
Conditions
HIV Infection
Interventions
Pegylated Interferon Alpha 2b (PEGINTRON)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Conditions
Melanoma
Interventions
Temozolomide (TMZ), Pegylated Interferon Alpha-2b (PGI)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Results available

Study of PEG-Intron for Plexiform Neurofibromas

NCT00396019
Conditions
Plexiform Neurofibroma
Interventions
PEG-Intron
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Months to 21 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 4 Interventional Results available

The SIM-SOF Trial for Hepatitis C

NCT02168361
Conditions
Chronic Hepatitis C
Interventions
Pegylated Interferon alfa-2b, Simeprevir, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Center For Hepatitis C, Atlanta, GA
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, gefitinib
Biological · Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Conditions
Chronic Hepatitis C
Interventions
Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
Drug
Lead sponsor
InterMune
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Brisbane, California
Conditions
Malignant Melanoma
Interventions
Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2031
U.S. locations
3
States / cities
San Diego, California • Memphis, Tennessee • Houston, Texas
Conditions
Chronic Hepatitis C, End Stage Renal Disease
Interventions
Ribavirin, Peginterferon, Boceprevir
Drug
Lead sponsor
Liver Institute of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Adult T-cell Leukemia-Lymphoma, ATLL
Interventions
Belinostat, Zidovudine, Interferon-Alfa-2b, Pegylated Interferon-Alfa-2b, Lymphodepleting Therapy
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 2 Interventional Results available

Medical Treatment of "High-Risk" Neurofibromas

NCT00846430
Conditions
Neurofibromatosis 1
Interventions
Peg-Interferon alpha-2b, Celecoxib (Celebrex), Temozolomide (temodar), Vincristine Sulfate (Oncovin)
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
2 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, GM-CSF, thalidomide
Biological · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Hepatitis C
Interventions
Eltrombopag, Antiviral therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
San Diego, California • New Haven, Connecticut • Honolulu, Hawaii + 3 more
Conditions
HIV Infections
Interventions
Peginterferon alfa-2b
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
0 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
21
States / cities
Berkeley, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 16 more
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
105
States / cities
Birmingham, Alabama • Dothan, Alabama • Fresno, California + 86 more
Conditions
Non-Hodgkins Lymphoma
Interventions
CHOP/Rituximab, PEG INTRON
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Hepatitis C
Interventions
Peginterferon-alpha-2b (PEG-Intron), Ribavirin, Epoetin-alpha (Procrit)
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Hepatitis C Infection
Interventions
Boceprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Riverside, California
Conditions
Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas
Interventions
Pegylated interferon alpha-2b
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Melanoma
Interventions
Sylatron, Yervoy
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Lymphoma, Precancerous/Nonmalignant Condition
Interventions
PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid, Zidovudine
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma
Interventions
Cisplatin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate, Peginterferon Alfa-2b, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Biological · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 40 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
186
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more